Kyverna Therapeutics, KYV-101 anti-CD19 CAR-T for lupus nephritis and neurological autoimmune disease (company programme)

Cited by name. No followable URL — the bibliographic record is the citation.

Authors. Kyverna Therapeutics

Venue. (company programme)

How the Institute flags it

frontier 1 time

Cited on 1 page

• Immune Engineering